IN8bio cuts costs on registrational delay
On the face of it IN8bio’s plan to go all in on its unmodified gamma-delta T-cell project INB-100, after promising early data at EHA in June, seems reasonable. But a closer look shows why the company needs the funds from a reprioritisation, announced yesterday, that will involve halving its workforce. IN8bio had hoped to go straight into a registrational study based on the phase 1 results, which came from an investigator-sponsored trial. But after meeting the FDA the company now says it will seek to add a control arm to the existing trial – presumably at the agency’s request. Meanwhile, enrolment into a 25-patient dose-expansion cohort is expected to complete in the first half of 2025. IN8bio’s August corporate presentation noted that the group could file an IND for a phase 2 randomised, controlled trial in the first half of 2025, and included a slide on the study’s design; this slide wasn’t included in the group’s September presentation. As well as cutting jobs, IN8bio is also deprioritising its glioblastoma candidates INB-200 and INB-400. The group’s stock was down 13% in premarket trading this morning.
In and out: IN8bio’s pipeline
| Project | Description | Indication | Status |
|---|---|---|---|
| Still active | |||
| INB-100 | Unmodified allogeneic gamma-delta T cells | AML | Ph1 investigator-sponsored trial; 25-pt expansion & control cohorts planned |
| INB-300 | Non-signalling Car-expressing gamma-delta T cells | TBD | Preclinical |
| INB-500 | Gamma-delta iPSC T cells | TBD | Preclinical |
| Deprioritised | |||
| INB-400 | Modified allogeneic/autologous gamma-delta T cells | Glioblastoma | Ph1/2; follow-up data due 2025 |
| INB-200 | Modified autologous gamma-delta T cells | Glioblastoma | Ph1; follow-up data due Q4 2024 |
Source: company presentation.
This story has been updated to reflect what was included in IN8bio's September presentation.
560
